Dacomitinib Approved, but Might Not Be Used.
The FDA approved the EGFR inhibitor dacomitinib as a first-line therapy for patients with metastatic, EGFR-mutant non-small cell lung cancer. However, the drug is unlikely to be used in clinical practice because four other EGFR inhibitors, including standard-of-care osimertinib, have already been approved.